NeoGenomics Operating Income Over Time
| NEO Stock | USD 12.38 0.09 0.72% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out NeoGenomics Performance and NeoGenomics Correlation. NeoGenomics | Build AI portfolio with NeoGenomics Stock |
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare NeoGenomics and related stocks such as Exagen Inc, MDxHealth SA ADR, and Stereotaxis Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XGN | (6.8 M) | (6.8 M) | (6.8 M) | (9.1 M) | (11.6 M) | (10.4 M) | (7.8 M) | (7.8 M) | (4.9 M) | (9.3 M) | (15.2 M) | (24.1 M) | (46.1 M) | (22.8 M) | (13.6 M) | (12.3 M) | (12.9 M) |
| MDXH | (7.1 M) | (9.2 M) | (11.8 M) | (16.1 M) | (15.3 M) | (14.4 M) | (12.8 M) | (12.3 M) | (32.1 M) | (43.2 M) | (27.1 M) | (26.8 M) | (37.9 M) | (27.3 M) | (24.7 M) | (22.2 M) | (23.4 M) |
| STXS | (10.9 M) | (31.9 M) | (10.6 M) | (8.8 M) | (5.4 M) | (5.4 M) | (6.4 M) | (5.9 M) | (2.5 M) | (4.8 M) | (6.7 M) | (12.9 M) | (18.8 M) | (21.8 M) | (24.7 M) | (28.4 M) | (29.9 M) |
| ACRS | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (8.5 M) | (20.7 M) | (48.6 M) | (72.4 M) | (135.4 M) | (111.1 M) | (50.9 M) | (89.7 M) | (89.9 M) | (97.4 M) | (141.9 M) | (127.7 M) | (121.4 M) |
| QTRX | (14.5 M) | (14.5 M) | (14.5 M) | (14.5 M) | (14.5 M) | (14.5 M) | (21.7 M) | (26 M) | (31.6 M) | (41.6 M) | (31.6 M) | (58.6 M) | (104.3 M) | (46 M) | (52.6 M) | (47.4 M) | (49.7 M) |
| SGMT | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (11.4 M) | (23.7 M) | (31.1 M) | (30.7 M) | (54.5 M) | (49 M) | (46.6 M) |
| SMTI | (702.2 K) | (5 M) | (5.4 M) | (2.9 M) | (2.1 M) | (965 K) | (272.1 K) | 120.4 K | (501.9 K) | (2.7 M) | (5 M) | (7.4 M) | (12.5 M) | (4.2 M) | (6.7 M) | (6 M) | (5.7 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.5 M) | (10.3 M) | (33.1 M) | (19.7 M) | (25.2 M) | (10.5 M) | (21.8 M) | (25.5 M) | (71.5 M) | (202.9 M) | 12.2 M | (78.2 M) | (95.7 M) | (86.1 M) | (81.8 M) |
| HUMA | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (85.7 M) | (64.6 M) | (81.2 M) | (84.6 M) | (100 M) | (114.4 M) | (103 M) | (108.1 M) |
| TKNO | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | 4.7 M | (12 M) | (49.7 M) | (35.6 M) | (26.1 M) | (23.5 M) | (24.7 M) |
NeoGenomics and related stocks such as Exagen Inc, MDxHealth SA ADR, and Stereotaxis Operating Income description
Operating Income is the amount of profit realized from NeoGenomics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of NeoGenomics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| NeoGenomics | NEO |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 9490 NeoGenomics Way, |
| Exchange | NASDAQ Exchange |
USD 12.38
Check out NeoGenomics Performance and NeoGenomics Correlation. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
NeoGenomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.